Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for Systemic Inflammation in CVID
NCT01946906Phase 4Completed
- Sponsor
- Oslo University Hospital
- Start
- Oct 2013
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rifaximin in common variable immunodeficiency (CVID), sponsored by Oslo University Hospital. Started Oct 2013; status: completed.
02
Drugs
rifaximin
03
Conditions
common variable immunodeficiency (CVID)
Beyond the preview
Go deeper on NCT01946906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01946906.